



## Maltese Former Employee Claim

**Perth, Australia & Malta – 7 March 2019** – Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”) announces that its wholly-owned subsidiaries AAT Research Limited and AAT Medical Limited, along with the Company’s founder Dr Adrian Attard Trevisan, have been named in legal proceedings filed in Malta by a former employee of AAT Medical.

The proceedings are primarily related to the alleged use of copyrighted material by Dr Attard Trevisan in a Doctoral Thesis in relation to epilepsy without due acknowledgement to the author, Dr Rudi Agius, at the time a full-time employee of AAT Research, engaged under contract as an Algorithm Researcher.

Dr Agius alleges that AAT Research and AAT Medical are jointly liable for loss and damages.

Neurotech believes the Plaintiff’s claims are without any basis in fact and in law. Other allegations being made in relation to Dr Attard Trevisan predate Neurotech and are not believed to be material to the company. The legal proceedings do not suggest Neurotech, AAT Research, AAT Medical and the associated Mente device, have breached any intellectual property.

Neurotech furthermore insists that this is a private matter between the plaintiff and Dr Attard Trevisan.

Dr Attard Trevisan has not been employed by the company in any full-time operational capacity since 2016 and in 2018 he resigned as director of the company. More recently he has been contracted as an independent advisor to provide a limited number of hours to review specific future projects that the company is considering.

The most recent iteration of the Mente device, released in 2018, delivers a brain training therapy that is based on widely-published research. The results of the Mente therapy have been independently verified in a US clinical trial (Carrick et al, 2018). The results show positive effects and a reduction of autistic behaviours. Furthermore, parents indicated significant improvements in social skills and communication of their children. The US trial validated the current version of Mente as a complementary home-based therapy for children with autism spectrum disorder.

Mente is helping autistic children to live better lives and we continue to work closely with families, clinics and the neuroscience community to further validate and improve the outcomes that Mente enables.

-ends-

### About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both

---

#### Neurotech International Ltd

ABN 73 610 205 402

Level 14, 191 St Georges Terrace

Perth, Western Australia 6060

[www.neurotechinternational.com](http://www.neurotechinternational.com)

accessible and affordable. Through flagship device Mente and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the screening and treatment of symptoms associated with conditions such as autism.

Mente is the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

Media enquiries

Matthew Wright

[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

Tel: +61 451 896 420